

Special Issue

Cancer Immunotherapy: Focus on Immune Checkpoint Inhibitors and Immune Modulators

Message from the Guest Editor

Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies, disrupt interactions between immune checkpoint molecules and their ligands, thereby restoring T-cell-mediated cytotoxicity against tumor cells. ICIs are extensively employed in the treatment of various cancers, offering significant therapeutic benefits to patients. However, their efficacy is often limited. Additionally, current biomarkers for ICI-mediated therapy, including microsatellite instability and PD-L1 expression levels in tumors and lymphocytes, are insufficient for accurately predicting therapeutic outcomes. This Special Issue focuses on the molecular mechanisms underlying ICI treatment resistance, the identification and validation of biomarkers for predicting ICI efficacy, and strategies for improving ICI efficacy by modulating the tumor microenvironment. Additionally, discussions on preclinical tests involving small-molecule compounds, antibodies, and similar agents are welcome.

Guest Editor

Dr. Katsuaki Ieguchi

Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan

Deadline for manuscript submissions

closed (30 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/208753

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)